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Abstract
Background: Brain metastases afflict approximately half of patients with metastatic melanoma (MM) and small cell
lung cancer (SCLC) and represent the direct cause of death in 60 to 70% of those affected. Standard of care
remains ineffective in both types of cancer with the challenge of overcoming the blood brain barrier (BBB)
exacerbating the clinical problem. Our purpose is to determine and characterize the potential of albendazole (ABZ)
as a cytotoxic and radiosensitizing agent against MM and SCLC cells.
Methods: Here, ABZ’s mechanism of action as a DNA damaging and microtubule disrupting agent is assessed
through analysis of histone H2AX phosphorylation and cell cyle progression. The cytotoxicity of ABZ alone and in
combination with radiation therapy is determined though clonogenic cell survival assays in a panel of MM and
SCLC cell lines. We further establish ABZ’s ability to act synergistically as a radio-sensitizer through combination
index calculations and apoptotic measurements of poly (ADP-ribose) polymerase (PARP) cleavage.
Results: ABZ induces DNA damage as measured by increased H2AX phosphorylation. ABZ inhibits the growth of
MM and SCLC at clinically achievable plasma concentrations. At these concentrations, ABZ arrests MM and SCLC
cells in the G2/M phase of the cell cycle after 12 hours of treatment. Exploiting the notion that cells in the G2/M
phase are the most sensitive to radiation therapy, we show that treatment of MM and SCLC cells treated with ABZ
renders them more sensitive to radiation in a synergistic fashion. Additionally, MM and SCLC cells co-treated with
ABZ and radiation exhibit increased apoptosis at 72 hours.
Conclusions: Our study suggests that the orally available antihelminthic ABZ acts as a potent radiosensitizer in MM
and SCLC cell lines. Further evaluation of ABZ in combination with radiation as a potential treatment for MM and
SCLC brain metastases is warranted.
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Introduction
Melanoma and small cell lung cancer (SCLC) have a
high propensity for metastasizing to the brain, account-
ing for the most common and third most common
cause of brain metastasis, respectively [1]. With no cur-
rently FDA-approved agents that cross the blood brain
barrier (BBB) to target SCLC, conventional therapy for
brain metastasis is limited to whole brain radiation ther-
apy. Even though SCLC is radiosensitive, patients receiv-
ing prophylactic cranial irradiation after a complete
response to chemotherapy still have a 33% 3-year brain
metastasis rate and only a 21% 3 year-overall survival
rate [2]. While the standard of care for melanoma brain
metastases is temozolomide (TMZ) and whole brain
radiation therapy (WBRT), this combination therapy
does not improve overall survival with this radioresistant
tumor [3,4]. The poor prognoses of SCLC and mela-
noma brain metastases highlight the need for an effec-
tive radiosensitizer that can cross the BBB and offer
more effective systemic therapy.
Recently, we have shown that mebendazole (MBZ), a
marketed benzimidazole (BZ) antihelminthic, is an effec-
tive anti-melanoma agent given its ability to disrupt
microtubule stability at clinically achievable concentra-
tions, thereby inducing apoptosis [5]. Albendazole (ABZ)
is another marketed antihelminthic that is structurally
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of crossing the BBB, a characteristic that is used to treat
parasitic infections of the central nervous system and
may be harnessed to potentially target brain metastasis
[6]. Although ABZ is structurally similar to MBZ, our
data suggests that ABZ also possesses DNA damaging
capabilities.
With both metastatic melanoma (MM) and SCLC
h a v i n gah i g hp r o p e n s i t yo fb r a i nm e t a s t a s e s ,w e
hypothesized that ABZ would be a potent chemothera-
peutic and radiosensitizing agent for melanoma and
SCLC brain metastases. We show here that at clinically
achievable plasma concentrations, ABZ decreases prolif-
eration, which correlates with arrest of the cancer cells
in the G2/M phase of the cell cycle. We establish that
ABZ radiosensitizes MM and SCLC and that this effect
is synergistic. Radiosensitization by ABZ is characterized
by enhanced radiation induced apoptosis.
Materials and methods
Cell culture
A375 and A2058 metastatic melanoma cells lines were
obtained from ATCC (Manassas, VA). H153 and H446
SCLC lines were generously provided by Drs. J. Don-
nington and H. Sauthoff (New York University School
of Medicine, New York, NY), respectively. All cell lines
were maintained in Dulbecco’s modified Eagle’s medium
supplemented with 10% fetal bovine serum, 5 units/mL
penicillin, and 5% glutamate. All cells were incubated at
a humidified atmosphere of 5% CO2 at 37°C. ABZ was
purchased from Sigma (St Louis, MO).
Cell Proliferation Assay
All cells were seeded in 96-well plates at a density of
5000 cells per well. After overnight incubation, cells
were treated with ABZ at concentrations ranging from
100 nM to 1000 nM. After 12 or 72 hr incubation peri-
ods, proliferation was assessed using a tetrazolium dye
reduction assay (CellTiter 96 AQueous Non-Radioactive
Cell Proliferation Assay; Promega, Madison, WI) [5].
Absorbance was recorded on a microplate reader at 495
nm. Cellular proliferation was expressed as a percentage
with vehicle-treated cells set at 100%. Each assay was
performed in triplicate with mean values reported.
Cell Cycle Analysis
A2058 and H153 cells were seeded at 50,000 cells/ml in
a1 0c m
2 tissue culture dish and incubated overnight.
Cells were treated with ABZ at 100 nM and 500 nM.
After 6, 12, 18, and 24 hrs, cells and media were col-
lected, washed with 1× PBS, and fixed in 70% ethanol at
4°C. Following incubation in ethanol, cells were washed
in phosphate citrate buffer (0.1 M citric acid, 0.2 M
Na2HPO4, pH 7.8), treated with 5 μgR n a s eAa n d
incubated in 10 μg propidium iodide solution (Sigma, St
Louis, MO). Cell-cycle distribution was determined by
flow cytometery of at least 10,000 gated cells using a
FACScan flow cytometer. All cell cycle analyses were
performed at least twice.
Clonogenic Survival Assay
Cells were seeded in 6 well plates at a density of 200-400
cells per well. After an 8 hr attachment period, cells were
treated with ABZ at 100 nM or 500 nM for 12 hrs. The
cells were then unirradiated (control) or irradiated with 6
MV photons (0.300 Gy/min) for total doses ranging from
1 to 8 Gy. Immediately after radiation, media containing
ABZ was exchanged for fresh media. Cells were subse-
quently cultured for approximately 2 weeks, with media
changed every third day. Next, colonies were stained with
0.1% crystal violet and counted. The percent plating effi-
ciency and surviving fraction were calculated based on
the survival of non ABZ treated, nonirradiated cells trea-
ted. Each assay was performed in doublet with the mean
reported.
Calculation of Radiation-ABZ Interactions
The results from the clonogenic assay measurements
were analyzed using Calcusyn software (Biosoft, Cam-
b r i d g e ,U K ) .T h ep r o g r a mc a l c u l a t e st h e“Combination
Index” [7] based upon the methods of Chou and Talalay
[8]. CI < 0.90 is indicative of synergistic interactions, CI
of 0.90 to 1.0 indicates additive interactions, and CI >
1.0 indicates antagonistic interactions.
Western Blot Analysis
A2058 and H153 cells were harvested after treatment
with 0, 100, or 500 nM ABZ for 12 hrs. Cells were then
irradiated at 2 or 10 Gy or left unirradiated as a control.
Immediately after radiation, media was changed and
cells were incubated for 72 hrs. Cells were then col-
lected, washed in ice cold 1× PBS, and harvested in an
extraction buffer (1% Triton X-100, 50 mmol/L Tris, 2
mmol/L EDTA, 150 mmol/L NaCl, pH 7.5) containing
protease inhibitor cocktail (Roche Applied Science,
Indianapolis, IN) and phosphatase inhibitor cocktail
(Sigma, St Louis, MO). The lysates were centrifuged at
14,000 × g, 4°C for 20 min in a microcentrifuge. The
protein concentrations of supernatants were measured
with a protein assay kit (Bio-Rad, Hercules, CA). Pro-
teins were separated by 12% SDS-PAGE and transferred
onto polyvinylidene difluoride membranes (Polyscreen,
Perkin-Elmer). For apoptotic studies, antibodies against
cleaved forms of poly (ADP-ribose) polymerase (PARP)
and caspase 9 were obtained from Cell Signaling Tech-
n o l o g y( D a n v e r s ,M A ) .F o rp H 2 A Xs t u d i e s ,m o u s e
monoclonal anti-pH2HAX IgG (Santa Cruz Biotechnol-
ogy, Santa Cruz, CA) was used. For all blots, anti-actin
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Immunoreactive bands were visualized using enhanced
chemiluminescence detection reagent (Perkin-Elmer,
Waltham, MA) and X-OMAT processing.
Statistics
Unless otherwise noted, experiments were performed in
triplicate. All data are presented as the average ± stan-
dard error of the mean (SEM). P-values were deter-
mined by a two-sided Student’s t-test with unequal
variance, with P < 0.05 considered significant.
Results
Albendazole treatment causes phosphorylation of H2AX
From a screen of 2000 compounds, we identified 4 BZs
that were selectively cytotoxic to melanoma cells as
compared to normal melanocytes [5]. In order to iden-
tify potential mechanisms of action for clinically relevant
BZs, the growth inhibitory properties of MBZ and ABZ
were examined in the NCI 60 cell screen as part of the
Developmental Therapeutics Program at the NCI/NIH.
The GI50 (concentration needed to achieve 50% growth
inhibition) data was then analyzed using COMPARE, an
algorithm that can predict possible mechanism(s) of
action for compounds based upon patterns of growth
inhibitory activity in the NCI 60 cell screen [9]. Based
upon this analysis, MBZ shared overlapping activity with
antimitotic agents such as rhioxin and paclitaxel (corre-
lation = 0.639 and 0.436, respectively). In contrast,
ABZ’s spectrum of activity is most similar to that of the
DNA damaging agent methyl-cyclonexyl-chloroethyl-
nitrosourea (methyl-CCNU; correlation = 0.636). There-
fore, we tested the hypothesis that ABZ acts as a DNA
damaging agent using phosphorylation of the histone
subunit as an indicator of DNA damage. Consistent
with the COMPARE results, treatment of MM and
SCLC cells with ABZ showed an increase in phosphory-
lation of a member of the histone H2A family, H2AX
(Figure 1). Cisplatin, a direct DNA damaging agent that
serves as a positive control, induced similar levels of
H2AX phosphorylation after treatment (Figure 1).
ABZ inhibits growth of MM and SCLC cells in vitro
Given ABZ’s ability to cross the BBB along with its joint
activity as a DNA damaging agent and microtubule
destabilizer, we sought to investigate its potential as a
radiosensitizer. Initially, we examined the effects of sin-
gle agent ABZ on the proliferation of two types of can-
cer with a high rate of brain metastasis: MM and SCLC.
Treatment with clinically achievable concentrations of
ABZ inhibited proliferation of both MM (A2058 and
A375) and SCLC (H153 and H446) cells. After 72 hr
treatment with 500 nM ABZ, a 37.8% inhibition of
A375 growth and 46.9% of A2058 growth was observed
(Figure 2b). Similarly, treatment with ABZ inhibited
SCLC cellular proliferation. H153 and H446 respectively
displayed 56.9% and 30.3% growth inhibition after treat-
ment with 500 nM ABZ for 72 hours (Figure 2b). Con-
centrations of ABZ greater than 500 nM did not result
in significant further growth inhibition in the cell lines
examined.
Albendazole induces cell cycle arrest at G2/M
Given ABZ’s well-characterized effects as a microtubule
disrupting agent [10], we wanted to determine if inhibi-
tion of cellular proliferation in MM and SCLC cells
might result from cell cycle arrest. In MM and SCLC
cells, ABZ arrests cells in the G2/M phase in a dose-
Figure 1 Albendazole treatment causes phosphorylation of
H2AX. A2058 melanoma cells received no treatment (-) or
treatment with 500 nM albendazole (ABZ) or 1 μM cisplatin (CIS) for
9 hr. Extracted proteins analyzed by Western blotting using an
antibody against phosphorylated H2AX with actin used as a loading
control.
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(Table 1). Specifically, after 12 hours of ABZ treatment,
the percent of A375 melanoma cells in the G2/M phase
increased from 4.7 to 65.2 upon treatment with 500 nM
ABZ. H153 and H446 SCLC and A2058 MM cells
showed a similar trend at 12 hr treatment with 500 nM
ABZ (Table 1), thereby indicating that ABZ causes
increased MM and SCLC cell accumulation at G2/M
phase of the cell cycle.
Albendazole radiosensitizes MM and SCLC cells
Because ABZ’sa c t i v i t ya sam i c r o t u b u l ei n h i b i t o ri s
similar to the radiosensitizing paclitaxel [11], we decided
to study ABZ’s radiosenitizing potential. It was impor-
tant to consider ABZ’s potential as a radiosensitizer at
shorter incubation periods given that the side effects in
humans are dose and time dependent. While 72 hr of
ABZ treatment resulted in growth inhibition of MM
and SCLC (Figure 2b), G2/M arrest was accompanied
by minimal growth inhibition in cell lines treated with
ABZ for 12 hr (Figure 2a). Therefore, we decided to
assess if ABZ can radiosensitize at shorter time points.
As shown in Figure 3, treatment with 500 nM ABZ pro-
moted radiation-induced clonogenic death in a dose-
dependent manner in A2058 and A375 melanoma cells
as well as H446 and H1530 SCLC cells. Survival fraction
at 2 Gy (SF2), calculated by dividing the number of sur-
viving clones at 2 Gy by the number of surviving clones
receiving no radiation or ABZ treatment, for A375 cells
was reduced from 61.6% in the irradiated-only controls
to 28.1% in ABZ treated and irradiated cells (Table 2).
A375 cells treated only with 500 nM ABZ for 12 hrs
showed a survival of 93.2% (Table 2; Figure 3). The SF2
for the combination treatment (28.1%) was greater than
the added effects of either radiation or ABZ alone
(Table 2). A2058 and SCLC cells also demonstrated
similar supra-additive responses to ABZ and radiation
(Figure 3; Table 2). Moreover, as depicted in Table 3
synergistic effects (CI < 0.90) on all 4 cells colony for-
mation were found when pretreated with 500 nM ABZ
followed by irradiating at 2 Gy. Although treatment at
100 nM decreased SF2 and demonstrated an additive
effect (CI = 0.90-1.0), the difference with irradiated-only
control cells was not statistically significant. Survival
enhancement ratios (SER10) were calculated at 10% cell
survival by dividing radiation dose of the radiation only
survival curve with that of the corresponding ABZ plus
radiation curve.
Albendazole enhances radiation-induced apoptosis in MM
and SCLC cells
Having established ABZ as a radiosensitizer, we decided
to characterize this effect by determining if pretreatment
with ABZ resulted in potentiation of radiation-induced
apoptosis as measured by levels of cleaved PARP, a mar-
ker of apoptosis. Figures 3a and 3b show that the com-
bination 12 hours of ABZ pretreament followed by
irradiation resulted in enhanced PARP cleavage as com-
pared to treatment with either agent alone. Because
both MM and SCLC cells demonstrated increased PARP
cleavage with the combination treatment compared to
the effects of radiation or ABZ alone. As an additional
marker of apoptosis, cleavage of caspase 9 was assessed
in MM and SCLC cells treated with ABZ and radiation
Figure 2 Albendazole inhibits proliferation of MM and SCLC
cells. A375 (○), A2058 (□), H1530 (◊) and H446 cells (Δ) were treated
with increasing concentrations of ABZ for 12 hours (A) or 72 hours
[2]. Points, mean from a minimum of four independent experiments.
Bars, SEM.
Table 1 Albendazole arrests cell in the G2/M phase in a
time and dose dependent fashion.
%G 2/M cells
Time (hr) ABZ (nM) A2058 A375 H1530 H446
0 0 10.6 4.7 4.3 0.9
12 100 10.0 13.1 3.0 5.2
12 500 29.3 65.2 38.6 47.7
12 1000 32.3 87.1 46.3 71.4
A2058 melanoma cells and H1530 SCLC cells were treated with ABZ
concentrations ranging from 100 to 1000 nM for 12 hr, stained with
propidium iodide, and analyzed for DNA content by flow cytometry. A total of
10 000 nuclei were analyzed from each sample, with the average of two
replicates reported.
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on the basis of clonogenic cell survival assays. H446 (A), H1530 [2], A375 (C) and A2058 (D) cells were treated with 0 (О), 100 (□), or 500 nM (Δ)
ABZ for 12 hr then irradiated as indicated. Cells were stained with crystal violet after being cultured for approximately 2 weeks. Points, average of
experiments each plated in duplicate. Bars, SEM. *, P < 0.05.
Table 2 ABZ induces a lower SF2 (ie supra-additive) than
the expected added SF2 (EAS) calculated by adding the
effect of radiation alone and ABZ alone.
% Survival
Cell line ABZ (nM) 0 Gy 2 Gy EAS
A375 0 100 61.6
100 101.3 57.8
500 93.2 28.1 53.8
A2058 0 100 85.0
100 93.4 76.2
500 80.2 56.8 64.8
H1530 0 100 62.8
100 89.4 58.9
500 80.5 37.1 43.3
H446 0 100 84.7
100 92.6 73.3
500 75.6 54.5 60.3
Table 3 Albendazole acts synergistically with radiation in
MM and SCLC cells.
% Survival
Cell line ABZ (nM) CI Values SER Plating Eff.
A375 100 0.981
500 0.701 1.45 43%
A2058 100 0.921
500 0.675 1.32 29%
H1530 100 0.89
500 0.528 1.28 34%
H446 100 0.906
500 0.485 1.20 26%
Combination Index values for ABZ and radiation. Values less than 0.9 indicate
a synergistic relationship, values between 0.9 and 1.0 indicate an additive
relationship, and values greater than 1.0 indicate an antagonistic relationship.
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receiving combination ABZ and radiation treatment
demonstrated enhanced levels of cleaved caspase 9 as
compared to treatment with either single agent alone.
Cleavage of caspase 9 is indicative of activation of the
intrinsic, mitochondrial-mediated apoptotic pathway. In
all 4 cell lines examined, the level of cleaved PARP and
caspase 9 observed in cells treated with 2 Gy irradiation
and ABZ were comparable to levels observed upon
treatment with 10 Gy irradiation alone. Altogether,
these data suggest that ABZ sensitizes these cells to
radiation induced apoptosis (Figure 4).
Discussion
Here, we demonstrate that ABZ, a BZ that effectively
c r o s s e st h eB B B ,i sc y t o t o x i ct oM Ma sw e l la sS C L C
(Figure 2). We found that this effect correlates with cel-
lular arrest at the G2/M phase of the cell cycle (Table
1). We show ABZ’s ability to act synergistically with
radiation through combination index analysis (Table 3).
ABZ achieves this effect in part by damaging DNA and
increasing radiation-induced apoptosis (Figure 1 and 4).
Our study has potential clinical significance. ABZ is
being explored as a potent in vitro and in vivo anti-neo-
plastic agent [12,13], and here we demonstrate that it
has further clinical potential as a radiosensitizer. The
radiation dose of 2 Gy used in this study closely approx-
imates the dose per fraction (2 to 3 Gy) used in patients
receiving WBRT for metastatic melanoma [14] or pro-
phylactic cranial irradiation for SCLC [3]. Additionally,
the concentration of ABZ employed in our studies is
readily achievable by oral administration [6]. A dose
escalation phase 1 clinical trial of ABZ in 33 patients
with a variety of metastatic cancers showed a maximum
achievable plasma concentration after oral administra-
tion to be 10.25 μM [15]. With other pharmacokinetic
studies showing that average cerebrospinal fluid (CSF)
concentration is approximately half the serum plasma
concentration [6], our in vitro concentration of 500 nM
is clinically achievable and well tolerated in patients
with brain metastases. Furthermore, we observe radio-
sensitization at concentrations significantly lower than
reported maximal CSF concentrations. At these lower
concentrations, the incidence of side effects is expected
to be reduced.
Like paclitaxel, ABZ is considered a spindle poison
[10]. At low clinical concentrations (less than 10% of
the maximum plasma achievable concentration in
humans), paclitaxel induces G2/M cell cycle arrest
[16,17]. With the G2/M phase being the most radiosen-
sitive phase, paclitaxel has been show to sensitize mela-
noma to radiation, inducing a SER of 1.2 at 40 nM [18].
Similarly, we show here that at low clinical concentra-
tions, ABZ arrests cells in the G2/M phase and radio-
sensitizes melanoma, inducing a higher SER of 1.39. We
hypothesize this difference in SER for comparable con-
centrations of ABZ and paclitaxel to be due to ABZ’s
ability to simultaneously induce DNA damage (Figure
1). Previous work has indicated that other BZ’s possess
DNA damaging capabilities [19,20]. Moreover, additional
studies have reported that paclitaxel-resistant cell lines
are sensitive to ABZ, suggestive of a mechanism of
action in addition to tubulin disruption [21,22]. Indeed,
data obtained from COMPARE suggesting that ABZ
possesses a spectrum of activity most similar to the
DNA damaging agent methyl-CCNU is consistent with
Figure 4 ABZ treatment potentiates apoptosis in irradiated melanoma and SCLC cells. A2058 and H1530 cells were treated with 500 nM
ABZ, 2 Gy or 10 Gy radiation, or indicted combination. Proteins were analyzed by Western blot hybridization with an antibody against cleaved
PARP (C-PARP) or cleaved caspase 9 (CC9) antibody. Actin served as loading control. NT = No treatment.
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clinical agent for radiosensitization because unlike pacli-
taxel, it can cross the BBB to target melanoma or SCLC
brain metastases. In conclusion, ABZ’s ability to cross
the BBB, radiosensitize cancer cells like melanoma and
SCLC which carry a high propensity for metastasizing to
the brain warrants further investigations of clinical
application.
Conclusion
The marketed anti-parasitic drug albendazole possesses
DNA damaging and microtubule disrupting capabilities.
Based upon this unique spectrum of activity as well as
its ability to cross the blood brain barrier, we examined
albendazole’s potential radiosensitization capabilities. At
clinically achievable concentrations, albendazole in com-
bination with irradiation causes enhanced apoptotic
induction in melanoma and SCLC, which have an
increased propensity to metastasize to the brain.
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